Last reviewed · How we verify
NCT04991051: HALO
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
trial in Fallopian Tube Cancer in 605 participants. Completed in 15 August 2022.
15 August 2022
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 605 |
| Start date | 2 May 2021 |
| Primary completion | 15 August 2022 |
| Estimated completion | 15 August 2022 |
| Sites | 24 locations across Russia, Saudi Arabia, United Arab Emirates, Oman, Qatar, Kuwait |
Conditions studied
- Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, female only, with Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To maximise the accessibility and benefit of PARP inhibitors to eligible patients, it is essential to know the prevalence of HRD in women with advanced high-grade serous or endometrioid ovarian cancer. Presently, the prevalence data for HRD are available from selected geographies only and range from 31% to 50%. Furthermore, the risk factors associated with HRD and clinical characteristics of patients with HRD need exploration for region-specific differences. In the present study, we will estimate the region- and country-specific prevalence of HRD in women with stage III or IV high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallopian tube cancer and associated risk factors with clinical characteristics in Asia-Pacific countries, Latin America, Africa, Russia, Australia, and Middle East countries. The findings of the study will help the oncologists in optimal patient selection and clinical decision-making for the first-line maintenance of patients with HGSOC
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE.
Al-Shamsi HO. · · 2022 · cited 3× · PMID 36412672 · DOI 10.3390/clinpract12060093 -
Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study.
Khokhlova S, Alnaqqash MA, Bahaj W, Bujassoum S, et al · · 2025 · cited 1× · PMID 40064569 · DOI 10.1016/j.ijgc.2025.101645 -
Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications.
Shash E, Vardar MA, Taskiran C, Boujassoum S, et al · · 2026 · PMID 41639797 · DOI 10.1186/s12885-025-15537-3 -
Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset.
Liou WS, Chao A, Sheu BC, Yeh LS, et al · · 2026 · PMID 41575336 · DOI 10.3802/jgo.2026.37.e55
Verify or expand the search:
- PubMed search for NCT04991051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fallopian Tube Cancer
Currently open trials in the same condition.
- NCT07402915 — Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian · Phase 1 · recruiting
- NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
- NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · Phase 2 · recruiting
- NCT07023484 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer · Phase 2 · recruiting
- NCT07460180 — The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cy · Phase 1, PHASE2 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04991051 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 6 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04991051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing